Wiping Out CGRP: Potential Cardiovascular Risks

详细信息    查看全文

• 作者：Antoinette MaassenVanDenBrink¹ ; ^{a.vanharen-maassenvandenbrink@erasmusmc.nl" class="auth_mail" title="E-mail the corresponding author} ; Joris Meijer² ; Carlos M. Villaló ; n³ ; Michel D. Ferrari²
• 关键词：CGRP ; migraine ; antibody ; cardiac ischemia ; cerebral ischemia
• 刊名：Trends in Pharmacological Sciences
• 出版年：2016
• 出版时间：September 2016
• 年：2016
• 卷：37
• 期：9
• 页码：779-788
• 全文大小：1701 K

文摘

Migraine is a common episodic neurovascular brain disorder associated with increased risk of cardio- and cerebrovascular ischemia. Migraine headache is likely caused by activation of the trigeminovascular system and release of calcitonin gene-related peptide (CGRP). Monoclonal antibodies against CGRP or its receptor are currently being evaluated for the prevention of migraine attacks. Preliminary efficacy data are promising. However, because CGRP may act as a vasodilatory safeguard during cerebral and cardiac ischemia, CGRP blockade could transform transient mild ischemic events into full-blown infarcts. Here, we review the cerebro- and cardiovascular risks that might be associated with CGRP blockade and which clinical and preclinical studies should be conducted to better assess the potential safety issues of this new promising class of drug.